Scilex Holding Company Warrant (SCLXW)

Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex’s CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulatory Approval and Commercialization for the Treatment of Lumbosacral Radicular Pain (LRP)/Sciatica

Scilex's majority-owned subsidiary Semnur Pharmaceuticals entered a $20 million private placement agreement with an investor. CEO Jaisim Shah will now focus full-time on Semnur, while Henry Ji becomes Scilex's new CEO, to advance SP-102's clinical development for lumbosacral radicular pain treatment.